Menu

Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic

Author:
  • C Winter
  • M P Nilsson
  • E Olsson
  • A M George
  • Y Chen
  • A Kvist
  • T Törngren
  • J Vallon-Christersson
  • C Hegardt
  • J Häkkinen
  • G Jönsson
  • D Grabau
  • M Malmberg
  • U Kristoffersson
  • M Rehn
  • S K Gruvberger-Saal
  • C Larsson
  • Å Borg
  • N Loman
  • L H Saal
Publishing year: 2016-08
Language: English
Pages: 8-1532
Publication/Series: Annals of Oncology
Volume: 27
Issue: 8
Document type: Journal article
Publisher: Oxford University Press

Abstract english

BACKGROUND: A mutation found in the BRCA1 or BRCA2 gene of a breast tumor could be either germline or somatically acquired. The prevalence of somatic BRCA1/2 mutations and the ratio between somatic and germline BRCA1/2 mutations in unselected breast cancer patients are currently unclear.

PATIENTS AND METHODS: Paired normal and tumor DNA was analyzed for BRCA1/2 mutations by massively parallel sequencing in an unselected cohort of 273 breast cancer patients from south Sweden.

RESULTS: Deleterious germline mutations in BRCA1 (n = 10) or BRCA2 (n = 10) were detected in 20 patients (7%). Deleterious somatic mutations in BRCA1 (n = 4) or BRCA2 (n = 5) were detected in 9 patients (3%). Accordingly, about 1 in 9 breast carcinomas (11%) in our cohort harbor a BRCA1/2 mutation. For each gene, the tumor phenotypes were very similar regardless of the mutation being germline or somatically acquired, whereas the tumor phenotypes differed significantly between wild-type and mutated cases. For age at diagnosis, the patients with somatic BRCA1/2 mutations resembled the wild-type patients (median age at diagnosis, germline BRCA1: 41.5 years; germline BRCA2: 49.5 years; somatic BRCA1/2: 65 years; wild-type BRCA1/2: 62.5 years).

CONCLUSIONS: In a population without strong germline founder mutations, the likelihood of a BRCA1/2 mutation found in a breast carcinoma being somatic was ∼1/3 and germline 2/3. This may have implications for treatment and genetic counseling.

Keywords

  • Cancer and Oncology

Other

Published
  • Lund Melanoma Study Group
  • Surgery Research
  • ISSN: 1569-8041
Åke Borg
Åke Borg
E-mail: ake [dot] borg [at] med [dot] lu [dot] se

Principal investigator

Oncology and Pathology, MV

+46 46 275 25 52

MV 404 C21B2

90

Project manager

Familial Breast Cancer

90

Professor

Oncology and Pathology, MV

MV 404 C21C2

90